OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Neurology is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)

Article	Citations
Lymphatic propagation of α-synuclein	480
Microglia, spreaders of Aβ seeds	422
Transmembrane protein interacts with α-synuclein to confer risk of PD	285
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	280
Ventricular enlargement caused by aducanumab	265
Getting specific: targeting Fc receptors in myasthenia gravis	253
Neural cell state shifts and fate loss in ageing and age-related diseases	232
Brain stimulation aids walking after spinal injury	232
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	218
Refining oxytocin therapy for autism: context is key	199
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	199
Global synergistic actions to improve brain health for human development	197
NODDI reveals brain microstructural changes in multiple sclerosis	195
Disease-specific modifications of tau protein	188
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	183
Continuous levodopa production by an artificial enzyme	183
The impact of rare genetic variants on Alzheimer disease	171
Spinal muscular atrophy treatment in utero	164
Nir Giladi (1955–2024)	159
Study reveals new ALS risk genes	147
Mitochondrial DNA instability in Huntington disease	147
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	133
TREM2 mediates phagocytosis in glioblastoma	133
Imperatives and co-benefits of research into climate change and neurological disease	132
Microglia subset associated with high-grade glioma	123

The Digitized Memory Clinic	122
SEQUINS — a new initiative to address disparities in neurology	120
The role of the gut microbiota in multiple sclerosis	117
Maternal immune activation and neuroinflammation in human neurodevelopmental disorders	115
Ultrasound lets gene therapy into the brain	113
Brain volume is associated with cognition in MS	105
Role for endogenous retrovirus in FTD	103
Menopause influences tau pathology	101
Amyloid plaques: hotspots for microglial turnover	99
Neurological care for LGBT+ people	98
Psychosis-causing lesions mapped to a hippocampal circuit	96
The challenges of anti-tau therapeutics in Alzheimer disease	93
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	89
Implications of AD plasma and PET biomarker discordance	89
Neuroinflammation predicts cognitive decline in FTD	89
MRI-based deep learning for TLE diagnosis	89
Diversity, equity and inclusion in neurology	88
Brain imaging illuminates cognitive impairment in multiple sclerosis	84
APOE ε4 influences Parkinson disease progression	84
Author Correction: Viral pathogens increase risk of neurodegenerative disease	79
Parkinson disease pathology can originate in the kidney	77
First trials test targeting of α-synuclein for Parkinson disease	77
Management of freezing of gait — mechanism-based practical recommendations	76
Precision neuroimmunology in multiple sclerosis — the horizon is near	76
Gene therapy for seizures in focal cortical dysplasia	73
α-Synuclein pathology as a target in neurodegenerative diseases	71
Evidence for altered astrocyte function in Duchenne muscular dystrophy	71
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	71
New IDEAS about amyloid, race and dementia disparities	70
Author Correction: Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	70
Food is brain medicine — relevance and translation to neurology	65
Neurosteroids alleviate seizures in rats	64
Glymphatic dysfunction in PD clinical progression	61
Thalamic inflammation — a therapeutic target for brain injury?	61
A new biological classification for Parkinson disease	60
Exosomal microRNA is promising biomarker in PD	60
Ultrasound ablation treatment for PD	58
Addressing disparities in neurology by building the workforce in LMICs	58
Coeliac disease as a model for understanding multiple sclerosis	58
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease	55
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	55
Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	54
Is Alzheimer disease a disease?	53
Spinal cord stimulation for the treatment of chronic pain	52
Synaptic degeneration in Alzheimer disease	52
The global and regional burden of diabetic peripheral neuropathy	52
The role of glial cells in multiple sclerosis disease progression	52
From the prodromal stage of multiple sclerosis to disease prevention	51
Apparent changes in the epidemiology and severity of multiple sclerosis	45
Hypothalamus loses control in migraine	44

Oligomeric tau could spread through synapses in AD	44
X-chromosome variants and PD in Latin America	43
Hypothyroidism is associated with dementia risk	43
Neurofilament light chain induces neuroinflammation	42
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence	42
Cognitive impairment and World Trade Centre-related exposures	42
Peripheral nervous system immune-related adverse events due to checkpoint inhibition	42
Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis	41
The inter-relationship between delirium and dementia: the importance of delirium prevention	41
Global epidemiology of migraine and its implications for public health and health policy	40
Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases	39
CAR T cells offer hope in glioblastoma	39
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management	38
Safety and efficacy of COVID-19 vaccines in people with neurological disorders	38
T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis	38
Dual function of biomolecular condensates	37
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction	36
Moving towards meaningful patient and public engagement	36
Risk locus for paediatric astrocytoma identified	35
α-Synuclein seeds in amyotrophic lateral sclerosis	34
Change in stroke outcomes over 20 years	34
New developments in guidelines for brain death/death by neurological criteria	33
Reactive astrocyte biomarkers mirror Alzheimer disease pathology	33
Multi-ancestry GWAS identifies 16 novel Alzheimer disease risk loci	33
Prognostic plasma biomarkers for spinal cord injury	33
Huntington disease-like 2: insight into neurodegeneration from an African disease	32
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology	32
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	32
Positron emission tomography in multiple sclerosis — straight to the target	32
Plasma extracellular vesicle biomarkers for frontotemporal dementia and related disorders	30
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	30
Inflammasomes in neurological disorders — mechanisms and therapeutic potential	28
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease	28
Origins and immunopathogenesis of autoimmune central nervous system disorders	27
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease	26
Twin study probes non-heritable immune aspects of multiple sclerosis	25
Deep learning distinguishes tauopathies	25
High rate of epilepsy in young individuals who died with COVID-19	24
Multiple sclerosis treatment blunts SARS-CoV-2 antibody response	24
Neurogenesis altered in multiple neurodegenerative diseases	24
Serum NfL as an MS biomarker	23
Charting brain development across the human lifespan	23
Genome-wide analysis furthers decoding of Alzheimer disease genetics	22
Does antiherpetic antiviral therapy reduce the risk of dementia?	21
The murky waters of sex differences in post-stroke cognitive impairment	21
Aberrant protein networks in Alzheimer disease	20
AI and protein structure and function in neurological disease: relevance to disease management	20
ALS pathogenesis linked to actin barrier collapse	20
John Q. Trojanowski	20
Author Correction: The complex aetiology of cerebral palsy	19
BCAS1+ oligodendrocytes aid remyelination in MS	19
Alzheimer disease in African American individuals: increased incidence or not enough data?	18
Pharmacological rehabilitation for stroke	17
AI aces diagnosis of chronic ataxias	17
Neurological manifestations of rhino-oculo-cerebral mucormycosis in the COVID-19 era	17
Pathogenetic mechanisms and treatment targets in cerebral malaria	16
Molecular biomarkers for vascular cognitive impairment and dementia	16
Neuroprognostication: a conceptual framework	16
Addressing disparities in the global epidemiology of stroke	16
Clocking the age of Parkinson disease onset	14
Effects of diet on MS onset and course	14
Nusinersen treatment response markers	13
Altered muscle cholesterol transport in ALS	13
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis	13
Alzheimer disease seen through the lens of sex and gender	13
Predictive tools in psychosis: what is ‘good enough’?	13
Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies	12
Addressing racial inequities in neuropsychological assessment requires international prescriptive standards, not demographically adjusted norms	11
Sex and gender in neurodevelopmental conditions	11
Mechanistic insights into the interaction between epilepsy and sleep	11
Nanoprobe for blood–brain barrier changes	11